



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

NSC 48160

Cat. No.:	HY-156328
CAS No.:	6640-90-0
Molecular Formula:	C ₁₈ H ₂₉ NO
Molecular Weight:	275.43
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (363.07 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	3.6307 mL	18.1534 mL	36.3069 mL	
		5 mM	0.7261 mL	3.6307 mL	7.2614 mL	
		10 mM	0.3631 mL	1.8153 mL	3.6307 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (9.08 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (9.08 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	NSC 48160 inhibits the growth of the pancreatic cancer cells with IC ₅₀ s of 84.3 μM for CPFAC-1 and 94.5 μM for BxPC-3. NSC 48160 also induces pancreatic cancer cell apoptosis. NSC 48160 can improve metabolic syndromes, such as NASH, obesity and lipid metabolism disorders ^{[1][2]} .
-------------	--

REFERENCES

- [1]. Li D, et al. A small-molecule induces apoptosis and suppresses metastasis in pancreatic cancer cells. Eur J Pharm Sci. 2013 Mar 12;48(4-5):658-67.
- [2]. Liu zuijia, et al. Application of small molecule compound NSC48160 in preparation of medicine for treating non-alcoholic fatty liver disease. Patent. CN115869292

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA